TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Training effectiveness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum FFA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycerol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average hemostatic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in magnetization transfer ratio (MTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: efficiency
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Simplified McGill score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of genetic testing for HFE-HH
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in CHD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve (AUC) and maximum plasma concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean distal cervical length after cerclage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: closeness
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Urine output during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ease of cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LES hypotonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: precramp contraction duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cramp EMG area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postcramp soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MFIS value
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Executive functioning deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Matrix reasoning scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mathematics scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG, IgA and IgM levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Experiencing harassment from male veterans
Endpoint domain: Adverse events/effects
Primary endpoint: Feeling unwelcome or unsafe at VHA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Missing needed care due to concerns about interacting with other veterans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Engagement of children and parents
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Proportion of children becoming non-anemic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thermal intensity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cold intensity and unpleasantness ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax (maximal L‐DOPA concentration reached)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (time at which the maximal L‐DOPA concentration was reached)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS‐III value for the best 'on state'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants achieving acceptable or excellent grand total scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: adverse LV remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: implant survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm delivery incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Rate of complete compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: dose of morphine necessary for titration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AQLQ12+ improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete or almost complete hair removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient grading of treatment superiority
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hair count analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean root-mean-square wavefront error of higher-order aberrations (HOAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β-cell function after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Activated T cells levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: exacerbation-related hospitalisations
Endpoint domain: Mortality/survival
Primary endpoint: poorer survival
Endpoint domain: Mortality/survival
Primary endpoint: Histological complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neoplastic progression
Endpoint domain: Adverse events/effects
Primary endpoint: Pain sensation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased stool frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fewer hard stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: less sensation of incomplete evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: serum levels of prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Resistance to administration of local anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-hour glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vo(2) peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success rate of treatment leading to intercourse at home
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of patients with urethral pain/burning
Endpoint domain: Adverse events/effects
Primary endpoint: ΔEELVVT (i - e)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ΔEELI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival without treatment-emergent grade 3/4 toxicity
Endpoint domain: Mortality/survival
Primary endpoint: Average day-time glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement on motor tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Diminished symptoms and signs of parkinsonism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative number of new enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of scans showing new enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Percentage of patients without enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: serum PICP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTc dispersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodily Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Lipid peroxidation (MDA and HNE levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: microleakage of pit and fissure sealant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dexloxiglumide C(max) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dexloxiglumide AUC increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implantation rate
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: HIV-1 risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adverse events leading to insert retrieval
Endpoint domain: Adverse events/effects
Primary endpoint: Time to AE resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum myostatin-to-follistatin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of water used for flushing during NBI endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total scores of HAMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of web-based logons
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: success of sensory block reaching T10 dermatome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median duration of T10 sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time of full motor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with the anaesthetic service
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PANDiet score increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Broadening of food repertoire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of dietary changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of reopening for excessive bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: median decrease in plasma viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects with viral load decrease > 1.0 log10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lumbar extensor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during muscle testing
Endpoint domain: Adverse events/effects
Primary endpoint: Choosing low-value care options
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hyperkalaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean peak serum potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acidaemia (pH levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in methylation levels in LINE1 repetitive elements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confirmed abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary artery catheter‐tip colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Unilateral motor and sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total (5-day) symptom score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline blood eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in eyebrow height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of total fat mass (FM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of total fat-free mass (FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of whole body total percentage of fat mass (FM%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental recovery of TOFr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: activities of daily life performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increase in daily FV servings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in FV servings in the past 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ST-segment resolution >50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected TIMI frame count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial culture positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: favorable response to antidepressant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in salivary S. mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive performance on attentional tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance on psychomotor speed tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negative mood and anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pain relief at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free outcome at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained pain-free outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nausea reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Venous access duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous access success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of health risks associated with childhood obesity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to aspirin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistence of dual antiplatelet therapy (DAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: risk of delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contractility recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CD4(+)/CD8(+) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentages of T‐cell subsets (CD3(+), CD4(+))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum neopterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum total soluble TL1A concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMA total score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agitation level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC of felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPPASI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index score reduction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PPPASI-50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median SCD (Specific IgE concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate to peanut SLIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom-free rate after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Peri-operative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed post-operative tonsillar bed healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of affective episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal ECP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical improvement after flunisolide therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impaired quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EMG values of the masseter muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean maximum CIMT progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS score for swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of headache per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average duration of headache episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on everyday activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive gains
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean time to perform the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective pain experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak BAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antral area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of motor nerve block
Endpoint domain: Adverse events/effects
Primary endpoint: Body temperature difference between acupoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minutes of moderate to vigorous activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients completely dry after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility of the urethra and bladder neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with persistent leakage of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucagon (GLC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Remission in patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28-ESR responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EMG preactivation of the erector spinae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fear avoidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of residual prolapse at 4 weeks postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of recurrence of prolapse at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transitions between stages of change
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Risk of stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chance of reversing stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes